IKT - Inhibikase Therapeutics, Inc.
2.11
-0.150 -7.109%
Share volume: 93,404
Last Updated: 04-25-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.01%
PREVIOUS CLOSE
CHG
CHG%
$2.26
-0.15
-0.07%
View ratios
| Fiscal Date | 03-31-2023 | 06-30-2023 | 09-30-2023 | 12-31-2023 | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-15-2023 | 08-14-2023 | 11-14-2023 | 03-27-2024 | 05-15-2024 | 08-14-2024 | 11-14-2024 | 03-27-2025 | |
| Assets | |||||||||
| Total Assets | 28.163 M | 22.347 M | 17.881 M | 14.507 M | 11.068 M | 8.827 M | 4.377 M | 98.600 M | |
| Current Assets | 27.629 M | 21.984 M | 17.551 M | 14.211 M | 10.808 M | 8.603 M | 4.190 M | 98.451 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 1.846 M | 969.152 K | 719.103 K | 958.996 K | 0.000 | 0.000 | 553.318 K | 0.000 | |
| Short Term Investments | 1.846 M | 969.152 K | 719.103 K | 958.996 K | 7.396 M | 4.854 M | 2.330 M | 41.053 M | |
| Total Receivables | 64.521 K | 79.604 K | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 25.718 M | 20.935 M | 16.832 M | 13.252 M | 2.353 M | 3.086 M | 913.420 K | 56.491 M | |
| Total Non-current Assets | 534.752 K | 363.615 K | 330.030 K | 295.599 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Property Plant Equipment | 231.489 K | 86.523 K | 79.940 K | 73.372 K | 66.804 K | 60.235 K | 53.667 K | 47.100 K | |
| Other Assets | 303.263 K | 277.092 K | 250.090 K | 222.227 K | 193.460 K | 163.762 K | 133.105 K | 101.437 K | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 28.163 M | 22.347 M | 17.881 M | 14.507 M | 11.068 M | 8.827 M | 4.377 M | 98.600 M | |
| Total liabilities | 2.842 M | 2.883 M | 2.863 M | 3.529 M | 4.291 M | 3.730 M | 4.907 M | 3.734 M | |
| Total current liabilities | 2.664 M | 2.733 M | 2.742 M | 3.439 M | 4.233 M | 3.705 M | 4.907 M | 3.734 M | |
| Accounts Payable | 959.078 K | 754.146 K | 734.561 K | 646.767 K | 1.294 M | 1.341 M | 2.529 M | 943.019 K | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current long term debt | 146.901 K | 147.966 K | 149.030 K | 531.879 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 178.110 K | 149.971 K | 121.013 K | 90.124 K | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 25.321 M | 19.464 M | 15.018 M | 10.978 M | 6.777 M | 5.097 M | -530.591 K | 94.866 M | |
| Common stock | 4.585 M | 5.226 M | 5.342 M | 6.179 M | 78.329 M | 81.608 M | 81.756 M | 189.324 M | |
| Retained earnings | -52.350 M | -58.128 M | -62.723 M | -66.901 M | -71.550 M | -76.510 M | -82.288 M | -94.421 M |
